Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Ilia L. Ferrusi, PhD(c)
Advertisement
Articles by Ilia L. Ferrusi, PhD(c)
Advertisement
Latest Updated Articles
- Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?
Published: May 17th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
